JTX-8064

Why wait? Celgene restructures a big Jounce pact — zeroing in on new I/O pathway with $530M deal and bumping ICOS
Endpoints
Tue, 07/23/19 - 07:53 pm
Celgene
Jounce Therapeutics
JTX-8064
macrophages